Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.
Regulatory T lymphocytes (Treg) infiltrate human glioblastoma (GBM); are involved in tumor progression and correlate with tumor grade. Transient elimination of Tregs using CD25 depleting antibodies (PC61) has been found to mediate GBM regression in preclinical models of brain tumors. Clinical trials...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2008-04-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC2291560?pdf=render |